このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ゲノム配列決定を使用して軟骨腫瘍および血管異常の背後にある遺伝子を解明する

軟骨腫瘍と血管異常を特徴とするメンデル疾患の原因遺伝子を特定するためのゲノムワイドシーケンシングと機能研究

Background:

Ollier disease (OD) and Maffucci syndrome (MS) are rare disorders that increase the risk of cancers in cartilage tissue. These tumors can lead to severe skeletal deformities beginning in childhood. People with OD or MS are also at an increased risk of blood vessel disorders and specific cancers. Researchers want to learn more about what causes these disorders.

Objective:

To understand the genetic causes of OD and MS.

Eligibility:

People aged 2 years and older who have OD or MS with cartilage tumors or blood vessel disorders.

Design:

Participants will stay at the NIH clinic for 5 days. They will undergo these procedures:

A physical exam with blood tests.

DXA (dual-energy X-ray absorptiometry) scan. The DXA scan measures the density of bones. Participants will lie on a table while a machine uses low-level X-rays to scan their body.

MRI (magnetic resonance imaging) scan. An MRI uses strong magnets to take pictures of the tissues inside the body. Participants will lie on a table that slides into a large tube. A contrast dye may be injected through a needle inserted into a vein in the arm.

X-rays. Some participants may have full-body X-rays instead of an MRI. X-rays take pictures of bones and other internal tissues and organs, such as the heart, lungs, and airways.

PET (positron emission tomography) and CT (computed tomography) scans. Adult participants will have 2 other scans. The PET scan will include a radioactive injection into a vein. They will also have a full-body CT scan.

調査の概要

状態

募集

条件

詳細な説明

Study Design:

The study will recruit and enroll up to 100 patients with Ollier disease (OD) and Maffucci syndrome (MS) over five years. Each participant will be seen at the NIH Clinical Center (CC) for an inpatient study visit of 5 days or longer.

During that visit, the following procedures will be performed: dual-energy x-ray absorptiometry (DXA), whole-body X-ray, magnetic resonance angiography (MRA), whole-body positron emission tomography (PET) scan, a magnetic resonance imaging (MRI), and brain single-voxel magnetic resonance spectroscopy. After being seen at the NIH CC by the study team, the participants will receive a summary of all the results of the tests and consults completed at the NIH.

Family members enrolled for genome sequencing will not undergo any clinical evaluations at the NIH CC.

Dr. Gordon will oversee the implementation of the study at the NIH. Dr. Marini was involved in the original NIH grant application and has retired but she retains an appointment at the NIH as a Scientist Emeritus/ Volunteer. Dr. Marini will serve on the protocol as a Senior Clinical Consultant and work at the NIH CC. She will not consent participants but will be present at many of the study visits.

Members of the JHU study team will have permission to work and/or observe at the NIH; they will however not be considered part of the NIH study team and will not be identified as NIH Associate Investigators.

Objectives:

Ollier disease (OD) and Maffucci syndrome (MS), are characterized by multiple enchondromas that result in severe skeletal deformities during early childhood and an increased risk for chondrosarcomas and other malignancies. Patients with MS also have vascular anomalies. Chondrosarcoma is a malignant tumor that originates from cartilaginous cells. It is the third most common primary malignancy of bone after myeloma and osteosarcoma. It accounts for about 20% of bone tumors and is diagnosed in approximately 600 patients each year in the United States. Up to 40% of the chondrosarcomas arise from an enchondroma. The risk for chondrosarcoma in OD is up to 45.8% and in MS up to 57.1%. Currently, the only treatment for patients with these disorders is surgical; there is no effective pharmacologic therapy.

We identified heterozygous germline loss of function variants in PTPN11 (encoding a non-receptor protein tyrosine phosphatase SHP2) causing MC. In preliminary studies, we also identified the PTPN11 R138X variant in a retiform hemangioendothelioma of a patient with MS and the germline PTPN11 L560F variant in a patient with OD. PTPN11 encodes SHP2, a cytosolic protein tyrosine phosphatase involved in an early step in RAS/MAPK signaling downstream of several receptor tyrosine kinases including EGFR and FGFR. Using immunoblot analysis we measured the expression of the end products of this pathway, pERK1 and 2 in fibroblasts from patients with MC and OD and observed decreased expression of pERK1 and 2 in patients compared to the controls (Sobreira et al., unpublished). Similarly, experiments in the Ptpn11 conditional knockout mouse models showed reduced ERK1/2 signaling in chondrocytes lacking SHP2. Taken together, these results suggest reduction RAS/MAPK signaling can lead to the formation of enchondromas. Heterozygous somatic variants of IDH1 and 2 have been identified in the tumors of a fraction of the patients with MS and OD. Neither variant was identified in the germline DNA of the affected individuals. And our preliminary studies have identified germline variants KDM4C and HIF1A, 2 genes known to interact with IDH1 and 2, as the candidate genes in 2 unrelated probands with multiple enchondromas.

On basis of these results, we hypothesize that OD and MS are tumor predisposition syndromes caused by germline variants such as neurofibromatosis type 1 and schwannomatosis. Subsequent hits in the same or different genes such as IDH1 and IDH2 or other as yet identified genes are involved in the formation of enchondromas and chondrosarcomas. Moreover, these variants likely down-regulate the RAS/MAPK pathway or are in genes that interact with IDH1 and 2.

To test this model, we will pursue the following Specific Aims:

Specific Aim 1. Comprehensively define the phenotypic features of patients with OD and MS.

Hypothesis: OD and MS are distinct under-characterized cancer susceptibility syndromes with diverse features. Recently, we proposed diagnostic and surveillance guidelines for systematic evaluation of patients with OD and MS9. Here, we will: (a) identify the complete set of phenotypic features characteristic of patients with OD and MS by performing detailed assessment of their clinical and family histories and physical features at the NIH/CC; (b) determine the number, size, and location of enchondromas and vascular anomalies and identify other tumors in these patients by performing full body MRI or X-ray, MRA , and brain magnetic resonance spectroscopy; and (c) establish a biobank of specimens from patients and family members for genetic, metabolic, and functional testing.

Specific Aim 2. Search for missing germline (and/or somatic mosaic) causative variants (coding and non-coding) in DNA from blood, enchondromas, chondrosarcomas and associated hemangiomas. We will perform WGS on germline and tumor (enchondroma, chondrosarcomas and hemangiomas) DNA to identify the germline variants in the blood and the subsequent hits involved in the tumor s formation. We will also do RNA sequencing (RNAseq) on RNA isolated from tumor samples to perform a gene expression analysis and identify other possible pathways affected in these disorders; and to aid to the interpretation of variants detected by WGS, especially synonymous and non-coding variants affecting splicing and RNA abundance, respectively.

Specific Aim 3. To test the hypothesis that standard analysis may overlook a causative variant because of an alternative mode of inheritance, we will apply novel analytic approaches that investigate alternative modes of inheritance typically not considered. We will investigate paternal and maternal imprinting modes of inheritance and investigate variants identified in the genes that escape X-inactivation. With WGS, we will also be able to investigate the variants in X-linked genes that escape X-inactivation and the variants in Y-linked genes.

Specific Aim 4. Determine the effect of causative variants of OD or MS in the HIF-1 pathway.

Hypothesis: Causative variants of OD and MS cause downregulation of HIF1A and its target genes. Our preliminary analysis of RNAseq data from fibroblast and enchondroma samples from patients with OD and MS showed impaired induction of HIF-1-related genes in contrast to other cancer settings. HIF1A variants have not been identified as disease-causing, but seven of our patients have a causative variant in this gene. We found that HIF1A and VHL were mutated at a higher rate among patients with OD and MS compared to controls (p<0.05). Therefore, we will: (a) use knock-in cell-based models to investigate the effect of the causative variants we identified in HIF1A (mutated in seven patients), VHL (mutated in six patients), and KDM4C (mutated in four patients) on HIF-1 transcriptional activity using a dual-luciferase assay40; and (b) identify differentially expressed genes and disrupted pathways with enchondroma RNAseq.

Specific Aim 5. Data Sharing. As we are doing in other projects, we will submit our sequence data to dbGaP to facilitate data sharing. The JHM IRB will make the determination that the sharing is consistent with the NIH genomic policy. Also, to identify others with data relevant to our candidate variants and genes, we will use GeneMatcher and the Matchmaker Exchange. We will also submit our data to ClinVar and COSMIC database. We are eager to participate in a consortium to establish the Kids First Data Resource and to the overall genetic dataset for childhood cancers at the NCI Genomic Data Commons.

研究の種類

観察的

入学 (推定)

100

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • 電話番号:TTY dial 711 800-411-1222
          • メール:ccopr@nih.gov

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~100年 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

100 patients with Ollier disease (OD) and Maffucci syndrome (MS)

説明

  • INCLUSION CRITERIA:

Patients >=2 years of age, male or female, of any ethnicity and age will be included if diagnosed with a disorder characterized by cartilage tumors or vascular anomalies.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_ONLY
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
Patients with Ollier disease (OD) and Maffucci syndrome (MS)

Patients with Ollier disease (OD) and Maffucci syndrome (MS).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Comprehensively define the phenotypic features of patients with OD and MS.
時間枠:5 years

Identify the complete set of phenotypic features characteristic of patients with OD and MS by performing a detailed assessment of their clinical and family histories and physical features at the NIH/CC.

5 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Identify and locate enchondromas, vascular anomalies, and other tumors with imaging techniques. Create a biobank of patient and family specimens for genetic and metabolic testing.
時間枠:5 years

Determine the number, size, and location of enchondromas and vascular anomalies and identify other tumors in these patients by performing whole-body MRI or X-ray, MRA, and brain magnetic resonance spectroscopy; and establish a biobank of specimens from patients and family members for genetic, metabolic, and functional testing.

5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Catherine M Gordon, M.D.、Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年1月27日

一次修了 (推定)

2030年12月31日

研究の完了 (推定)

2030年12月31日

試験登録日

最初に提出

2024年12月21日

QC基準を満たした最初の提出物

2024年12月26日

最初の投稿 (実際)

2024年12月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月29日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD that underlie results in a publication will be deposited into a data repository in line with NIH regulations.

IPD 共有時間枠

In line with publication of results.

IPD 共有アクセス基準

De-identified datasets used to generate results presented in manuscripts will be deposited into a repository that can be publicly accessible in line with NIH regulations. In compliance with ethical standards and institutional policies, other access to individual participant data will be governed by a structured data-sharing framework to ensure participant privacy and confidentiality. Access to IPD will be granted under a Data Use Agreement that specifies permissible uses, prohibits re-identification or further data sharing, and requires secure storage and handling of data. Access will be restricted to de-identified or coded datasets, with direct identifiers removed.

IPD 共有サポート情報タイプ

  • SAP
  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する